Overview

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)

Status:
Completed
Trial end date:
2016-01-31
Target enrollment:
Participant gender:
Summary
To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD.
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
Forest Laboratories